Prelude Therapeutics Stock Price on April 25, 2024
| PRLD Stock | USD 0.98 0.02 2.08% |
Below is the normalized historical share price chart for Prelude Therapeutics extending back to September 25, 2020. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Prelude Therapeutics stands at 0.98, as last reported on the 27th of November, with the highest price reaching 0.99 and the lowest price hitting 0.96 during the day.
If you're considering investing in Prelude Stock, it is important to understand the factors that can impact its price. Prelude Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of -0.35, which implies the firm had a -0.35% return per unit of risk over the last 3 months. Prelude Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Prelude Therapeutics' Risk Adjusted Performance of (0.26), coefficient of variation of (279.90), and Variance of 41.95 to confirm the risk estimate we provide.
At present, Prelude Therapeutics' Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. . At present, Prelude Therapeutics' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting. The current year's Price To Book Ratio is expected to grow to 1.14, whereas Price To Operating Cash Flows Ratio is forecasted to decline to (2.53). Prelude Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 25th of September 2020 | 200 Day MA 3.7779 | 50 Day MA 1.6895 | Beta 1.546 |
Prelude |
Sharpe Ratio = -0.3533
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PRLD |
Estimated Market Risk
| 6.63 actual daily | 59 59% of assets are less volatile |
Expected Return
| -2.34 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.35 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Prelude Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Prelude Therapeutics by adding Prelude Therapeutics to a well-diversified portfolio.
Price Book 0.3338 | Enterprise Value Ebitda (0.54) | Price Sales 17.6883 | Shares Float 13.7 M | Wall Street Target Price 5.4 |
Prelude Therapeutics Valuation on April 25, 2024
It is possible to determine the worth of Prelude Therapeutics on a given historical date. On April 25, 2024 Prelude was worth 3.99 at the beginning of the trading date compared to the closed value of 4.04. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Prelude Therapeutics stock. Still, in general, we apply an absolute valuation method to find Prelude Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Prelude Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Prelude Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 3.87 | 4.13 | 3.87 | 3.87 | 28,584 | |
04/25/2024 | 3.99 | 4.09 | 3.99 | 4.04 | 115,746 |
| 4.05 | 4.07 | 3.99 | 4.07 | 18,553 |
| Backtest Prelude Therapeutics | | | Prelude Therapeutics History | | | Prelude Therapeutics Valuation | Previous | Next |
Prelude Therapeutics Trading Date Momentum on April 25, 2024
| On April 26 2024 Prelude Therapeutics was traded for 4.07 at the closing time. The top price for the day was 4.07 and the lowest listed price was 3.99 . The trading volume for the day was 18.6 K. The trading history from April 26, 2024 was a factor to the next trading day price growth. The trading delta at closing time against the next closing price was 0.74% . The trading delta at closing time against the current closing price is 3.96% . |
Prelude Therapeutics Fundamentals Correlations and Trends
By evaluating Prelude Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Prelude Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Prelude financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Prelude Therapeutics Stock history
Prelude Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Prelude is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Prelude Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Prelude Therapeutics stock prices may prove useful in developing a viable investing in Prelude Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 60.4 M | 48.3 M | |
| Net Loss | -103.9 M | -109.1 M |
Prelude Therapeutics Quarterly Net Working Capital |
|
Prelude Therapeutics Stock Technical Analysis
Prelude Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Prelude Therapeutics Period Price Range
Low | November 27, 2024
| High |
0.00 | 0.00 |
Prelude Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Prelude Therapeutics November 27, 2024 Market Strength
Market strength indicators help investors to evaluate how Prelude Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Prelude Therapeutics shares will generate the highest return on investment. By undertsting and applying Prelude Therapeutics stock market strength indicators, traders can identify Prelude Therapeutics entry and exit signals to maximize returns
Prelude Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Prelude Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Prelude Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Prelude to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.26) | |||
| Jensen Alpha | (2.47) | |||
| Total Risk Alpha | (3.33) | |||
| Treynor Ratio | (1.85) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Prelude Stock analysis
When running Prelude Therapeutics' price analysis, check to measure Prelude Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prelude Therapeutics is operating at the current time. Most of Prelude Therapeutics' value examination focuses on studying past and present price action to predict the probability of Prelude Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prelude Therapeutics' price. Additionally, you may evaluate how the addition of Prelude Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Stocks Directory Find actively traded stocks across global markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |